An overview of the current treatment landscape of non-Hodgkin lymphoma
Novel agents for myeloma related bone disease
Lessons from the ASPIRE trial: three drug regimens as the new SOC for relapsed MM
Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al.
Cessation of venetoclax and remaining in remission from CLL?